Note 8 - Subsequent Events
|6 Months Ended|
Jun. 30, 2021
|Notes to Financial Statements|
|Subsequent Events [Text Block]||
8. Subsequent Events
In addition to the subsequent events discussed elsewhere in these notes, see below for a discussion of the Company's subsequent events occurring after June 30, 2021.
In July 2021, the Company amended its Sponsored Laboratory Study Agreement with MD Anderson for total payment of $0.2 million to support the continuation of the project.
On August 10, 2021, the Company entered into a portfolio development advisory agreement with an entity affiliated with Dr. Waldemar Priebe. In connection with the services to be provided pursuant to the agreement, the Company agreed to issue the entity a-year warrant to purchase 250,000 shares of Company common stock with an exercise price of which was equal to the market price of the Company’s common stock on the effective date of the agreement. The warrant vest as follows: (a) 50% vests upon execution of the agreement, provided the advisor does not terminate the agreement prior to the end of the one-year term; and (b) 50% vests 60 days after the end of the one-year term, subject to the Company’s Board of Directors determining that the services to be provided have been adequately performed; provided that the warrant shall vest in full upon a change of control event.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef